Sotera Health Company (NASDAQ:SHC) Stock Has Consensus Price Target of $21.38 According to Analysts

Sotera Health Company (NASDAQ:SHC) has received an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $21.38.

A number of research analysts recently issued reports on SHC shares. JPMorgan Chase & Co. restated an “underweight” rating and set a $17.00 price target on shares of Sotera Health in a research note on Wednesday, October 14th. Wall Street Zen downgraded shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays increased their price target on shares of Sotera Health from $19.00 to $22.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Citigroup boosted their target price on Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised Sotera Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th.

Insider Activity at Sotera Health

In other Sotera Health news, insider Michael P. Rutz sold 150,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $18.84, for a total value of $2,826,000.00. Following the completion of the transaction, the insider directly owned 334,279 shares in the company, valued at approximately $6,297,816.36. The trade was a 30.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the transaction, the chairman owned 3,969,393 shares of the company’s stock, valued at $73,433,770.50. The trade was a 17.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,294,515 shares of company stock valued at $23,999,528 over the last ninety days. 15.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SHC. BlackRock Inc. acquired a new position in Sotera Health in the second quarter worth about $428,635,000. Sculptor Capital LP bought a new position in shares of Sotera Health during the second quarter worth about $426,000,000. Jupiter Topco LLC acquired a new stake in shares of Sotera Health in the second quarter valued at approximately $149,137,000. Two Seas Capital LP acquired a new stake in Sotera Health in the 2nd quarter valued at approximately $103,590,000. Finally, Lakewood Capital Management LP bought a new stake in shares of Sotera Health during the second quarter valued at about $70,638,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Stock Performance

Shares of SHC stock opened at $17.64 on Tuesday. The firm has a fifty day moving average price of $18.64 and a 200 day moving average price of $17.22. The company has a market cap of $5.03 billion, a P/E ratio of 30.95 and a beta of 1.85. Sotera Health has a 12 month low of $13.09 and a 12 month high of $19.85. The company has a current ratio of 2.80, a quick ratio of 2.55 and a debt-to-equity ratio of 3.33.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. The firm had revenue of $321.38 million during the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 earnings per share. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Sell-side analysts predict that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.